A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

NCT01007097 Phase 2 COMPLETED

The purpose of this study is to determine the safety and efficacy of multiple doses of TAK-875, once daily (QD), in subjects with Type 2 Diabetes Mellitus.

Details

Lead sponsor	Takeda
Phase	Phase 2
Status	COMPLETED
Enrolment	426
Start date	2009-12
Completion	2010-09

Conditions

• Diabetes Mellitus, Type 2

Interventions

• TAK-875
• TAK-875
• TAK-875
• TAK-875
• TAK-875
• Glimepiride
• Placebo

Primary outcomes

• Change from Baseline in Glycosylated Hemoglobin at Week 12. — Baseline and Week 12

Countries

United States, Guatemala, Mexico